Cybin remains in a high-risk, pre-revenue development phase, characterized by significant quarterly operating losses that peaked at $58.3 million in 2025Q2. While the company maintains a cash position of $118.7 million as of 2026Q1, the emergence of $44.5 mill...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 9, 2026 | -$0.38+28.3% vs -$0.53 | — vs — |
Q4 2025 Nov 13, 2025 | -$1.39-87.8% vs -$0.74 | — vs — |
Q3 2025 Aug 14, 2025 | -$1.10-115.7% vs -$0.51 | — vs — |
Q3 2025 Aug 13, 2025 | -$1.10-115.7% vs -$0.51 | — vs — |
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year.
Benchmark CYBN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cybin Inc. (CYBN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.09 | $303.86M | -13.66 | — | — | -42.76% | — | |
| $13.75 | $1.86B | -4.46 | — | — | -398.21% | — | |
| $42.79 | $3.23B | -20.77 | — | — | -102.48% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $1.77 | $2M | -0.24 | — | -8269.53% | -81.74% | — | |
| $112.44 | $13.34B | 43.92 | 37.55% | 24.86% | 180.63% | — |
Cybin Inc. (CYBN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CYBN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cybin Inc. (CYBN) stock FAQ — growth, dividends, profitability & financials explained
Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.
Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.
Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.
